BTIG raised the firm’s price target on Organogenesis (ORGO) to $9 from $7 and keeps a Buy rating on the shares. With the changes in reimbursement set to take effect in 2026, there will be clear share winners and share losers, and the firm believes that Organogenesis will be one of those that may be a share winner based on its current product pricing structure relative to the finalized pricing structure at $127.28 per cm, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORGO:
- Organogenesis Holdings Surpasses Revenue Guidance Amid Challenges
- Organogenesis Holdings Reports Record Revenue, Raises Guidance
- Organogenesis Holdings’ New Study on Diabetic Foot Ulcers: A Potential Game-Changer?
- Buy Rating for Organogenesis Holdings Despite Mixed Trial Results, Supported by Diversified Revenue and FDA Clearance Efforts
- Organogenesis Holdings Faces Setback in ReNu Phase 3 Trial